Cancer Breakthroughs. Realized. We help transform groundbreaking cancer-related research and innovation in Ontario into viable commercial opportunities that benefit patients, researchers, investors and Ontario's economy.

About

We know the business of science.

Funds

We bridge the funding gap.

Investment Opportunities

We are the gateway to Ontario's oncology assets.

Jeff Courtney, in Memoriam

Saying goodbye to FACIT's friend and visionary-in-chief.

Jeff was a fantastic leader in the OICR-FACIT family and the broader Ontario life sciences community.


FACIT's Year in Review (2017)

Seeding world class oncology innovation: a look back at 2017

We hope 2017 was a prosperous year for you, our partners in health innovation.  While FACIT had many successes this year..... 


FACIT Features: OICR Launches CTIP Initiative

FACIT congratulates OICR on launching CTIP to drive Ontario's most promising cancer drugs towards the clinic.

The Clinical Therapeutics Innovation Pipeline (CTIP) will support the local translation of Ontario discoveries into therapies with the potential for improving the lives of patients with cancer. Ten projects were selected in this highly competitive funding round, and reflect the strength of the province’s collaborative network and drug discoveries.


FACIT Welcomes Kevin Empey, Cynthia Goh and Shana Kelley to the Board of Trustees

FACIT expands Board to advance mandate to drive Ontario cancer breakthroughs.

New Trustees join existing Trustees, Mr. Greg Gubitz and Mr. John Morrison, bringing additional financial, entrepreneurial and biotech industry expertise.


FACIT Features: Turnstone and AbbVie Announce Collaboration

FACIT Congratulates Portfolio Company Turnstone Biologics on Transformative Collaboration with AbbVie

Turnstone Biologics, a startup co-founded by FACIT, announced a research, option and license agreement with AbbVie Inc. for up to three of Turnstone's next-gen oncolytic viral immunotherapies. This partnership deepens the Ontario roots established by FACIT and its co-founders, expanding the scale of innovative research and local career opportunities for scientists. 


FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations

FACIT congratulates Fusion on completing the second closing of their Series A, now oversubscribed at US$46M, with new investors joining including Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc. FACIT participated in both, this latest closing and as an early seed investor in Fusion.


FACIT Launches Cross-border Campaign to Recruit Clinical Scientists and Biotechnology Industry Executives

Initiative targets expats for growing oncology company portfolio in Ontario

FACIT is expanding and updating its database of US-based industry advisors for roles ranging from investment diligence to full time management roles in Ontario-based biotech start-ups. 


FACIT Announces Investment in 3 Ontario Start-ups Under Prospects Fund

FACIT invests first round of Prospects Fund in Radialis Medical, KA Imaging, and DNAstack.

Ontario start-ups Radialis Medical of Thunder Bay, KA Imaging of Kitchener, and DNAstack of Toronto are the first to receive capital from FACIT's new Prospects Oncology Fund for proof-of-concept development of breakthrough cancer technologies.


FACIT Builds on Commercialization Momentum by Attracting Experienced Executive-in-Residence

Anil Amlani expands FACIT’s oncology expertise in medical device sector

Anil Amlani joins FACIT with strong executive and transactional experience, broadening the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.


First Patient Treated in Turnstone's Lung Cancer Trial Combining Novel Viral Cancer Therapy with Approved Checkpoint Inhibitor

Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing.

Turnstone announced that treatment has been initiated on the first patient in the company's Phase I/II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1-MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody.


Latest Tweet / Follow

Contact Us